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Brigitte Adams is the founder of Eggsurance.com who froze her own eggs in her late 30s (for $19,000). In 2014, she posed for a Bloomberg 
Business cover story: “Freeze Your Eggs, Free Your 
Career.”1 Put childbearing on ice to level the playing 
field and open opportunities at work.2 When Adams 
tried to use her own frozen eggs at 45, however, she 
was unable to get pregnant. Adams is “still positive 
about egg freezing,” but “not positive about how it’s 
being marketed.”3 
Michelle Bayefsky argues that fertility companies 
mislead millions of American women, including the 
10,000+ who have paid to freeze their eggs.4 She 
makes the case that corporate claims to “stop time” 
or “freeze fertility” — while stopping short of explicit 
assurances — still cross the line of informed consent 
and truthful advertising. Her analysis of this land-
scape adds critical evidence to calls for transparency 
in the multi-billion-dollar market for reproductive 
services.5
Egg freezing ads focus on choice and control. But 
the science is out on how reliably frozen eggs result in 
live births. Individuals and couples who roll the dice 
for a chance at biological parenthood are entitled to 
know the risks and benefits going in. But misleading 
claims risk preying on the dreams that egg freezing 
can make possible, leaving too many with overblown 
expectations and no legal recourse. 
These arguments revive old questions about 
advances in reproductive freedom and the fraction of 
society who can take advantage of its newest forms.6 
This reflection gestures toward two issues that Bayef-
sky does not take up: (1) history and (2) access. Nei-
ther omission diminishes the force of her findings. But 
both provide essential context for appreciating its full 
implications. 
First, we have been here before. American fertility 
clinics have long overstated people’s chances of taking 
home a baby by using criteria such as the number of 
eggs retrieved and number of embryo transfers, rather 
than the number of live births.7 Some have even sought 
to signal success rates by offering splashy money-back 
guarantees (albeit ultimately to a fraction of uniquely 
low-risk patients).8
Public outrage over inflated fertility clinic success 
rates brought federal and state regulation in the early 
1990s.9 But it wasn’t enforced. By 1996, an Ameri-
can Medical Association report found that “deceptive 
advertising and insufficient informed consent” were 
rampant in assisted reproduction.10 Bayefsky isn’t the 
first to show such marketing still wants for clarity and 
candor. The New York Times ran a recent profile on 
the fertility industry’s “Misleading Promise to Those 
over 40.”11
The only federal regulation doesn’t do enough. A 
1992 law asks clinics to report how often IVF patients 
get pregnant. But there’s no penalty for failing to com-
ply.12 And it’s unclear whether consumers seek out this 
information anyway. Bayefsky calls for oversight by 
the Federal Trade Commission. But she misses deeper 
anxieties — from across the ideological terrain — that 
help explain the FTC’s longstanding indifference to 
fertility markets.13 
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The second point is that red tape could make repro-
ductive services available to fewer people. Just fifteen 
states mandate insurance coverage to treat infertility.14 
Freezing eggs already costs anywhere from $6,000 to 
$20,000 for just one cycle, plus another $500/year 
for storage, with total costs to make a baby this way 
around $100,000 — at a time when median house-
hold income is half that.15 If transparency require-
ments would raise prices, what’s an acceptable trade-
off with affordability?
Limits on access are not spread evenly, either. 
Recent surveys suggest just 4% of women who froze 
their eggs are African American, despite their higher 
rates of infertility.16 Insurance coverage and truth in 
advertising are important first steps. But these dispar-
ities probably also owe to in part egg freezing ads and 
brochures about “maternal ‘empowerment’ that center 
on elite white women” and shame or isolate women of 
color through marketing that leaves out their images 
and stories.17 The promotion of fertility services should 
be honest, yes, but inclusive too.
Note
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